Jun 30, 2023
Simon Allen is the CEO and Director of Anebulo Pharmaceuticals, which focuses on finding an effective treatment for acute cannabinoid intoxication or ACI, particularly in an emergency department setting. ACI is a condition where an individual has consumed or smoked too much cannabis or products that contain THC or synthetic cannabis and is experiencing symptoms of psychosis, anxiety, elevated heart rate, or is unresponsive. Their drug ANEB-001 is designed to address the cause of the symptoms without the need for traditional methods like benzodiazepines and beta blockers, which have their risks.
Simon explains, "What we are seeing is individuals taking these high-potency edibles, for example, and also smoking and vaping. These are other forms that can create ACI outcomes. And essentially, they're out for several hours, if not overnight, in the hospital. This can get as serious as the escalation to a psychiatric ward if the individual is so psychotic, agitated, and anxious that the emergency department can't handle it or chooses not to handle it and pushes it to the psychiatric ward. And those expenses are in the tens of thousands of dollars to the healthcare system. Not only that, there are extremely poor patient outcomes."
"What's important is that these molecules, the synthetic ones, are, unfortunately extremely strong binders to the CB1 receptor and do more to stimulate effectively. And very, very small doses of these synthetic cannabinoids can create very poor patient outcomes simply because they're much tighter binders to the CB1 receptor compared to THC. And when they do bind to that receptor, they're much more active. And so the street names like K2 and Spice are examples."
@AnebuloP #AnebuloPharmaceuticals #ACI #AcuteCannabinoidIntoxication #Cannabis #Overdose
